Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 9, 2020
Reporting Period: Event-based (June 9, 2020)
Business Context: The Company, an emerging growth company incorporated in Delaware, announced the entry into a material definitive agreement for a registered direct offering and concurrent private placement of equity securities.
Key Financial Metrics
Transaction Overview:
- Aggregate Purchase Price: $5,217,000
- Estimated Net Proceeds: Approximately $4.7 million (after deducting placement agent fees and transaction expenses)
- Use of Proceeds: Working capital purposes
Securities Issued:
- Common Stock: 2,820,000 shares issued in a registered direct offering.
- Warrants: Warrants to purchase up to 2,115,000 shares of Common Stock.
- Warrant Terms: Five-year term; exercise price of $2.00 per share; immediately exercisable; cashless exercise available if not registered within six months.
Transaction Costs:
- Placement Agent Fee: 7% of the aggregate purchase price paid by investors placed by the agents.
- Expense Reimbursement: Up to $50,000 for certain expenses.
Note: This filing does not provide historical revenue, profit, cash flow, margin, debt, or liquidity metrics for the Company.
Material Changes
This filing reports a discrete capital raise event rather than a periodic financial performance update. The material change is the execution of a Securities Purchase Agreement and Placement Agency Agreement on June 9, 2020, resulting in the commitment of $5,217,000 in gross capital from accredited investors.
Guidance, Outlook, and Risks
Management Commentary and Outlook:
- The Company expects the Offering to close on or about June 11, 2020, subject to customary closing conditions.
- The Company expects to file a prospectus supplement for the Registered Offering on or about June 10, 2020.
Risks and Contingencies:
- Closing Conditions: The transaction is subject to the satisfaction of customary closing conditions in the Purchase Agreement and Placement Agency Agreement.
- Placement Agent Obligation: Placement Agents (Maxim Group LLC and Joseph Gunnar & Co., LLC) have no obligation to purchase any securities or arrange for a specific dollar amount; they are acting on a "reasonable best efforts" basis.
- Registration Status: Warrants are immediately exercisable but may be exercised on a cashless basis if the Warrant Shares are not registered six months after issuance.
Investor Verification Checklist
- Verify the final closing date of the Offering (expected June 11, 2020) and confirm receipt of net proceeds.
- Review the filed Prospectus Supplement (expected June 10, 2020) for final terms of the Registered Offering.
- Confirm the exact number of shares issued and warrants granted upon closing.
- Monitor the registration status of the Warrant Shares to determine if cashless exercise provisions become active.
- Review the full text of the Placement Agency Agreement (Exhibit 10.1) and Securities Purchase Agreement (Exhibit 10.2) for specific covenants and indemnification rights.